Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Nyxoah SA despite higher revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Nyxoah is expected to report a quarterly loss of $0.61 per share, reflecting a year-over-year change of -10.9% [3]. - Revenues are projected to be $1.95 million, which is an increase of 40.3% compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 6.1% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Nyxoah is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +19.67% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a potential earnings beat, particularly when combined with a strong Zacks Rank [10]. - Nyxoah currently holds a Zacks Rank of 4, making it challenging to predict an earnings beat despite the positive Earnings ESP [12]. Historical Performance - In the last reported quarter, Nyxoah was expected to post a loss of $0.62 per share but actually reported a loss of -$0.63, resulting in a surprise of -1.61% [13]. - Over the past four quarters, Nyxoah has only beaten consensus EPS estimates once [14]. Industry Comparison - In the Zacks Medical Info Systems industry, Hims & Hers Health, Inc. is expected to report earnings of $0.09 per share, indicating a year-over-year change of +50% [18]. - Hims & Hers Health's revenue is expected to be $583.68 million, up 45.4% from the previous year [19].

Core Insights - electroCore, Inc. (ECOR) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended September 2025 [1] - The upcoming earnings report is expected to be released on November 5, with the stock's movement likely influenced by whether the actual results meet or exceed expectations [2] Financial Expectations - The consensus estimate indicates a quarterly loss of $0.36 per share, reflecting a year-over-year change of -16.1% [3] - Revenues are projected to be $7.85 million, representing a 19.9% increase from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised down by 4.08% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for electroCore is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.41% [12] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictive power for positive readings [9][10] - electroCore's current Zacks Rank is 3, making it challenging to predict an earnings beat [12] Historical Performance - In the last reported quarter, electroCore was expected to post a loss of $0.32 per share but actually reported a loss of -$0.35, resulting in a surprise of -9.38% [13] - Over the past four quarters, the company has only beaten consensus EPS estimates once [14] Industry Comparison - In the Zacks Medical - Drugs industry, Madrigal (MDGL) is expected to report a loss of $1.99 per share, with a significant year-over-year revenue increase of 300.8% to $249.15 million [18][19] - Madrigal's consensus EPS estimate has been revised up by 29.2% in the last 30 days, and it has a positive Earnings ESP of +27.84%, indicating a likely earnings beat [19][20]

Core Viewpoint - Wall Street anticipates flat earnings for Evolus, Inc. (EOLS) in the upcoming quarter, with revenues expected to increase, making the comparison between actual results and estimates crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate predicts a quarterly loss of $0.19 per share, unchanged from the previous year, while revenues are projected to be $67.82 million, reflecting an 11% increase year-over-year [3]. - The consensus EPS estimate has remained stable over the last 30 days, indicating a lack of significant reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Evolus is lower than the consensus estimate, resulting in an Earnings ESP of -2.70%, suggesting a bearish outlook from analysts [12]. - Despite the negative Earnings ESP, Evolus holds a Zacks Rank of 2 (Buy), complicating predictions of an earnings beat [12]. Historical Performance - Evolus has not surpassed consensus EPS estimates in the last four quarters, with the most recent quarter showing a significant miss of -166.67% [13][14]. Industry Comparison - CeriBell, Inc. (CBLL), another player in the medical products industry, is expected to report a loss of $0.43 per share, marking a year-over-year change of +76.8%, with revenues anticipated at $21.79 million, up 26.8% from the previous year [18]. - CeriBell's consensus EPS estimate has been revised 2.3% higher in the last 30 days, resulting in a positive Earnings ESP of +6.10%, indicating a likelihood of beating the consensus EPS estimate [19].

Core Viewpoint - Elanco Animal Health is expected to report flat earnings of $0.13 per share for the quarter ended September 2025, with revenues projected at $1.09 billion, reflecting a 5.9% increase year-over-year [1][3]. Earnings Report Expectations - The earnings report is scheduled for November 5, and better-than-expected results could lead to a stock price increase, while disappointing results may cause a decline [2]. - Management's discussion during the earnings call will be crucial in determining the sustainability of any immediate price changes and future earnings expectations [2]. Estimate Revisions - The consensus EPS estimate has been revised down by 2.15% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Elanco is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -5.88%, complicating predictions for an earnings beat [12]. Earnings Surprise History - In the last reported quarter, Elanco was expected to post earnings of $0.20 per share but actually delivered $0.26, resulting in a positive surprise of +30.00% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [14]. Investment Considerations - Despite the negative Earnings ESP, the stock holds a Zacks Rank of 2, indicating a potential for positive performance, although it does not strongly suggest an earnings beat [12][17]. - Investors are advised to consider other factors beyond earnings surprises when making investment decisions regarding Elanco [15][17].

Core Viewpoint - Freshworks Inc. is expected to report a year-over-year increase in earnings and revenues for the quarter ended September 2025, with a consensus outlook indicating potential stock price movement based on actual results compared to estimates [1][2]. Earnings Expectations - The upcoming earnings report is anticipated to be released on November 5, with expected earnings of $0.13 per share, reflecting an 18.2% increase year-over-year, and revenues projected at $208.62 million, up 11.8% from the previous year [3][2]. Estimate Revisions - The consensus EPS estimate has been revised down by 11.11% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, which complicates predictions of an earnings beat [12]. Historical Performance - Freshworks has a history of beating consensus EPS estimates, having done so in the last four quarters, including a notable surprise of +50.00% in the last reported quarter [13][14]. Zacks Rank - The stock currently holds a Zacks Rank of 1 (Strong Buy), which typically increases the likelihood of a positive earnings surprise, although the lack of a positive Earnings ESP reading makes predictions uncertain [12][10].

Core Viewpoint - The market anticipates a year-over-year decline in earnings for Blue Owl Capital Corporation despite an increase in revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Blue Owl Capital Corporation is expected to report quarterly earnings of $0.39 per share, reflecting a year-over-year decrease of 17% [3]. - Revenues are projected to be $461.57 million, which is an increase of 13.7% compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 0.52% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Blue Owl Capital is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -3.85% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likelihood of actual earnings deviating from consensus estimates, with positive readings being more predictive of earnings beats [9][10]. - Blue Owl Capital's current Zacks Rank is 4, which complicates the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Blue Owl Capital was expected to post earnings of $0.39 per share but actually reported $0.40, resulting in a surprise of +2.56% [13]. - Over the past four quarters, the company has only surpassed consensus EPS estimates once [14]. Industry Comparison - Oportun Financial Corporation, another player in the financial services industry, is expected to report earnings of $0.26 per share, indicating no change year-over-year, with revenues expected to decline by 4.5% [19]. - Oportun Financial's consensus EPS estimate has been revised down by 3% in the last 30 days, leading to an Earnings ESP of -13.73% [20].

Core Viewpoint - Payoneer Global Inc. (PAYO) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending September 2025, with actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for November 5, and if the results exceed expectations, the stock may rise; conversely, a miss could lead to a decline [2]. - The consensus estimate for quarterly earnings is projected at $0.06 per share, reflecting a year-over-year decrease of 45.5%, while revenues are expected to reach $263.46 million, marking a 6.1% increase from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 19.06% higher, indicating a collective reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Payoneer Global is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.63%, suggesting a bullish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Payoneer Global currently holds a Zacks Rank of 3, which, along with the positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Payoneer Global was expected to post earnings of $0.06 per share but only achieved $0.05, resulting in a surprise of -16.67% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Conclusion - While Payoneer Global is viewed as a potential earnings-beat candidate, other factors should also be considered when evaluating the stock ahead of its earnings release [17].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Q2 Holdings (QTWO) due to higher revenues, with actual results being crucial for stock price movement [1][2] Earnings Expectations - Q2 Holdings is expected to report earnings of $0.55 per share, reflecting a year-over-year increase of +96.4% [3] - Revenues are projected to be $197.46 million, up 12.8% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 1.05% lower in the last 30 days, indicating a reassessment by analysts [4] - A positive Earnings ESP of +2.75% suggests recent bullish sentiment among analysts, despite a Zacks Rank of 4 indicating a sell [12] Earnings Surprise History - In the last reported quarter, Q2 Holdings had an expected EPS of $0.51 but delivered $0.50, resulting in a surprise of -1.96% [13] - The company has only beaten consensus EPS estimates once in the last four quarters [14] Industry Context - In the Zacks Internet - Software industry, Spotify (SPOT) is expected to report earnings of $1.87 per share, a year-over-year change of +17.6% [18] - Spotify's revenue is anticipated to be $4.92 billion, up 12.3% from the previous year, but the consensus EPS estimate has been revised down by 5% [19]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Recursion Pharmaceuticals due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Company Summary - Recursion Pharmaceuticals is expected to report a quarterly loss of $0.38 per share, reflecting an 11.8% decrease year-over-year [3]. - Projected revenues for the quarter are $17.45 million, down 33.1% from the same quarter last year [3]. - The consensus EPS estimate has been revised down by 4.27% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Most Accurate Estimate for Recursion Pharmaceuticals is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +18.42% [11]. - Despite the positive Earnings ESP, the stock has a Zacks Rank of 4, complicating predictions of an earnings beat [11]. - The company has not surpassed consensus EPS estimates in the last four quarters, with a previous surprise of -17.14% [12][13]. Industry Context - Niagen Bioscience, another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report an EPS of $0.02, unchanged from the previous year, with revenues projected at $31.3 million, up 22.4% [17]. - Niagen Bioscience has an Earnings ESP of -33.33% and a Zacks Rank of 4, making it difficult to predict an earnings beat [19].

Core Viewpoint - The market anticipates that Senseonics Holdings (SENS) will report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended September 2025, with a focus on how actual results compare to estimates [1][2]. Financial Expectations - The consensus estimate indicates a quarterly loss of $0.33 per share, reflecting a year-over-year improvement of +58.8% [3]. - Expected revenues are projected to be $8.1 million, representing a significant increase of 90.1% from the same quarter last year [3]. Estimate Revisions - Over the past 30 days, the consensus EPS estimate has been revised down by 5.56%, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Senseonics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -20.00%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from consensus estimates, but it is more reliable for positive readings [9][10]. - Senseonics currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Senseonics was expected to post a loss of $0.40 per share, matching the actual result with no surprise [13]. - Over the last four quarters, the company has only beaten consensus EPS estimates once [14]. Industry Comparison - Another company in the medical technology sector, Inspire Medical Systems (INSP), is expected to report a loss of $0.09 per share, indicating a year-over-year change of -115%, with revenues projected at $221.44 million, up 9% from the previous year [18][19]. - Inspire Medical Systems has an Earnings ESP of +68.18% and has consistently beaten consensus EPS estimates in the past four quarters, indicating a more favorable outlook compared to Senseonics [20].